FI3470063T3 - Lääkekoostumuksia cftr-välitteisten sairauksien hoitoon - Google Patents
Lääkekoostumuksia cftr-välitteisten sairauksien hoitoon Download PDFInfo
- Publication number
- FI3470063T3 FI3470063T3 FIEP18192504.1T FI18192504T FI3470063T3 FI 3470063 T3 FI3470063 T3 FI 3470063T3 FI 18192504 T FI18192504 T FI 18192504T FI 3470063 T3 FI3470063 T3 FI 3470063T3
- Authority
- FI
- Finland
- Prior art keywords
- compound
- substantially amorphous
- pharmaceutical composition
- weight
- composition
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 11
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940125782 compound 2 Drugs 0.000 claims 12
- 229940125904 compound 1 Drugs 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims 2
- 239000007962 solid dispersion Substances 0.000 claims 2
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000007888 film coating Substances 0.000 claims 1
- 238000009501 film coating Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 claims 1
- PURKAOJPTOLRMP-UHFFFAOYSA-N ivacaftor Chemical compound C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O PURKAOJPTOLRMP-UHFFFAOYSA-N 0.000 claims 1
- UFSKUSARDNFIRC-UHFFFAOYSA-N lumacaftor Chemical compound N1=C(C=2C=C(C=CC=2)C(O)=O)C(C)=CC=C1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 UFSKUSARDNFIRC-UHFFFAOYSA-N 0.000 claims 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims 1
- 235000019341 magnesium sulphate Nutrition 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261721622P | 2012-11-02 | 2012-11-02 | |
| US201261728328P | 2012-11-20 | 2012-11-20 | |
| US201361770668P | 2013-02-28 | 2013-02-28 | |
| US201361824005P | 2013-05-16 | 2013-05-16 | |
| US201361840668P | 2013-06-28 | 2013-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3470063T3 true FI3470063T3 (fi) | 2025-03-05 |
Family
ID=50628072
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18192504.1T FI3470063T3 (fi) | 2012-11-02 | 2013-11-01 | Lääkekoostumuksia cftr-välitteisten sairauksien hoitoon |
| FIEP13792149.0T FI2914248T4 (fi) | 2012-11-02 | 2013-11-01 | Farmaseuttisia koostumuksia cftr-välitteisten tautien hoitamiseksi |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP13792149.0T FI2914248T4 (fi) | 2012-11-02 | 2013-11-01 | Farmaseuttisia koostumuksia cftr-välitteisten tautien hoitamiseksi |
Country Status (30)
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1664006A2 (en) | 2003-09-06 | 2006-06-07 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| BR122018075478B8 (pt) | 2004-06-24 | 2023-10-31 | Vertex Pharma | moduladores de transportadores de cassete de ligação de atp |
| EP1912983B1 (en) | 2005-08-11 | 2011-06-08 | Vertex Pharmaceuticals, Inc. | Modulators of cystic fibrosis transmembrane conductance regulator |
| ES2778846T3 (es) | 2005-11-08 | 2020-08-12 | Vertex Pharma | Moduladores heterocíclicos de transportadores de casete de unión a ATP |
| HUE032813T2 (en) | 2005-12-28 | 2017-11-28 | Vertex Pharma | Solid forms of N- [2,4-bis (1,1-dimethyl ethyl) -5-hydroxyphenyl] -1,4-dihydro-4-oxoquinoline-3-carboxamide |
| USRE50453E1 (en) | 2006-04-07 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| ES2580803T3 (es) | 2006-04-07 | 2016-08-26 | Vertex Pharmaceuticals Incorporated | Moduladores de transportadores del casete de unión a ATP |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| CA2686838C (en) | 2007-05-09 | 2017-03-14 | Vertex Pharmaceuticals Incorporated | Modulators of cftr |
| CN101827593B (zh) | 2007-08-24 | 2013-07-24 | 沃泰克斯药物股份有限公司 | 用于治疗(特别是)囊性纤维化的异噻唑并吡啶酮 |
| SI2217572T1 (sl) | 2007-11-16 | 2014-05-30 | Vertex Pharmaceuticals Incorporated | Izokinolinski modulatorji prenaĺ alcev z atp-vezavno kaseto |
| CN101910156B (zh) | 2007-12-07 | 2013-12-04 | 沃泰克斯药物股份有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的固体形式 |
| MX364936B (es) | 2007-12-07 | 2019-05-15 | Vertex Pharma | Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos. |
| US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| NZ703814A (en) | 2008-02-28 | 2016-06-24 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| HUE035160T2 (en) | 2009-03-20 | 2018-05-02 | Vertex Pharma | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| RU2579370C2 (ru) | 2010-04-07 | 2016-04-10 | Вертекс Фармасьютикалз Инкорпорейтед | Твердые формы 3-(2, 2-дифторбензо[d][1, 3] диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты |
| AR081760A1 (es) | 2010-04-07 | 2012-10-17 | Vertex Pharma | Una composicion farmaceutica para administracion oral que comprende acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico, un metodo para producir la misma, una tableta y una forma unitaria de dosificacion oral que la comprende y el uso de la misma para la fabricacion de un medicamento |
| MX353408B (es) | 2010-04-22 | 2018-01-11 | Vertex Pharma | Proceso para producir compuestos de cicloalquilcarboxamido-indol. |
| HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
| EP2776427B1 (en) | 2011-11-08 | 2017-02-01 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| ES2982694T3 (es) | 2012-01-06 | 2024-10-17 | H Lundbeck As | Compuestos de carbamato para su uso en tratamiento |
| CA2865519C (en) | 2012-02-27 | 2018-01-02 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl0-5-hydroxyphenyl-1]-1,4-dihydro-4-oxoquinolone-3-carboxamide for treating cystic fibrosis |
| EP2872122A1 (en) | 2012-07-16 | 2015-05-20 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
| DK2914248T4 (da) * | 2012-11-02 | 2024-01-02 | Vertex Pharma | Farmaceutiske sammensætninger til behandlingen af cftr medierede sygdomme |
| US9303918B2 (en) * | 2013-03-15 | 2016-04-05 | Monosol Rx, Llc | Process for drying a wet film with control of loss on drying |
| WO2014176553A1 (en) * | 2013-04-26 | 2014-10-30 | Vertex Pharmaceuticals Incorporated | Correctors acting through msd1 of cftr protein |
| RU2016122882A (ru) * | 2013-11-12 | 2017-12-19 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний |
| MX387720B (es) | 2014-04-15 | 2025-03-12 | Vertex Pharma | Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de conductancia de transmembrana de fibrosis quística. |
| CN112279808B (zh) | 2014-10-06 | 2024-03-08 | 弗特克斯药品有限公司 | 囊性纤维化跨膜转导调节因子调节剂 |
| EP3204358B1 (en) | 2014-10-07 | 2018-09-19 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| MX381732B (es) | 2014-11-18 | 2025-03-13 | Vertex Pharma | Proceso para efectuar la prueba de alto rendimiento de la cromatografia liquida de alta resolucion. |
| BR112017024253A2 (pt) | 2015-05-11 | 2018-07-24 | Abide Therapeutics Inc | métodos de tratamento de inflamação ou dor neuropática. |
| WO2017053711A2 (en) | 2015-09-25 | 2017-03-30 | Concert Pharmaceuticals, Inc. | Deuterated cftr potentiators |
| WO2017151725A1 (en) * | 2016-03-03 | 2017-09-08 | Nivalis Therapeutics, Inc. | Formulations of an s-nitrosoglutathione reductase inhibitor |
| ES2946970T3 (es) | 2016-03-31 | 2023-07-28 | Vertex Pharma | Regulador de conductancia transmembrana de moduladores de fibrosis quística |
| HUP1600269A2 (hu) | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Lumacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyászati készítményei |
| US10383865B2 (en) | 2016-04-25 | 2019-08-20 | Druggability Technologies Ip Holdco Limited | Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them |
| HUP1600271A2 (hu) * | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei |
| HUP1600270A2 (hu) | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Ivacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadott készítményei |
| US10376501B2 (en) | 2016-04-25 | 2019-08-13 | Druggability Technologies Ip Holdco Limited | Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| US10206915B2 (en) | 2016-04-25 | 2019-02-19 | Druggability Technologies Ip Holdco Limited | Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| HUE056716T2 (hu) | 2016-09-30 | 2022-03-28 | Vertex Pharma | Cisztás firbrózis transzmembrán konduktancia regulátor modulátora, gyógyszerészeti készítmények, kezelési eljárások, és eljárások a modulátor elõállítására |
| CA3043609A1 (en) * | 2016-11-16 | 2018-05-24 | Abide Therapeutics, Inc. | Pharmaceutical formulations |
| HUE056973T2 (hu) | 2016-11-16 | 2022-04-28 | H Lundbeck As | MAGL inhibitor kristályos formája |
| CN110267948B (zh) | 2016-12-09 | 2023-12-08 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法 |
| BR112019025801A2 (pt) | 2017-06-08 | 2020-07-07 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
| AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| ES2912657T3 (es) | 2017-08-02 | 2022-05-26 | Vertex Pharma | Procesos para preparar compuestos de pirrolidina |
| AU2018351533B2 (en) | 2017-10-19 | 2023-02-02 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
| SG11202004264VA (en) | 2017-12-01 | 2020-06-29 | Vertex Pharma | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| KR102716244B1 (ko) | 2017-12-08 | 2024-10-14 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법 |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| UA126304C2 (uk) | 2018-02-15 | 2022-09-14 | Вертекс Фармасьютикалз Інкорпорейтед | Макроцикли як модулятори муковісцидозного трансмембранного регулятора провідності, їх фармацевтичні композиції, застосування їх для лікування муковісцидозу та спосіб їх виготовлення |
| WO2019195739A1 (en) | 2018-04-05 | 2019-10-10 | Alexander Russell Abela | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2019200246A1 (en) | 2018-04-13 | 2019-10-17 | Alexander Russell Abela | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| PT3880197T (pt) | 2018-11-14 | 2023-05-09 | Vertex Pharma | Métodos de tratamento para a fibrose quística |
| AR118555A1 (es) | 2019-04-03 | 2021-10-20 | Vertex Pharma | Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| WO2020214921A1 (en) | 2019-04-17 | 2020-10-22 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cftr |
| BR112022002605A2 (pt) | 2019-08-14 | 2022-05-03 | Vertex Pharma | Formas cristalinas de moduladores de cftr |
| WO2021030556A1 (en) | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| UY38837A (es) | 2019-08-14 | 2021-02-26 | Vertex Pharma | Proceso de elaboración de moduladores de cftr |
| US11904006B2 (en) | 2019-12-11 | 2024-02-20 | University Of Iowa Research Foundation | Poly(diaminosulfide) particle-based vaccine |
| MX2022013224A (es) | 2020-04-21 | 2022-11-14 | H Lundbeck As | Sintesis de un inhibidor de la monoacilglicerol lipasa. |
| WO2022194399A1 (en) | 2020-07-13 | 2022-09-22 | Idorsia Pharmaceuticals Ltd | Macrocycles as cftr modulators |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| US20230374038A1 (en) | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225750A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230373939A1 (en) | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2022076621A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225748A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230416275A1 (en) | 2020-10-07 | 2023-12-28 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| MX2023004073A (es) | 2020-10-07 | 2023-07-05 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica. |
| CN116783204A (zh) | 2020-10-07 | 2023-09-19 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控因子的调节剂 |
| US20230365587A1 (en) | 2020-10-07 | 2023-11-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2022076622A2 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| JP2023552828A (ja) | 2020-12-10 | 2023-12-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症の治療方法 |
| US20240100183A1 (en) * | 2020-12-11 | 2024-03-28 | University Of Iowa Research Foundation | Compositions comprising molecules for cystic fibrosis treatment |
| US20240189299A1 (en) * | 2021-03-09 | 2024-06-13 | Laurus Labs Limited | Oral film of cftr modulator(s) |
| TW202333699A (zh) | 2022-02-03 | 2023-09-01 | 美商維泰克斯製藥公司 | 囊腫纖維化之治療方法 |
| JP2025505643A (ja) | 2022-02-08 | 2025-02-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症膜コンダクタンス制御因子の調節因子 |
| PE20250606A1 (es) | 2022-04-06 | 2025-02-26 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica |
| US20250332151A1 (en) | 2022-05-16 | 2025-10-30 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| CA3267788A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | COMBINATION OF MACROCYCLIC CFTR MODULATORS WITH CFTR CORRECTORS AND/OR CFTR POTENTIALIZERS |
| CA3267795A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | MACROCYCLICAL CFTR MODULATORS |
| WO2024056779A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Crystalline form of (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide |
| WO2025076235A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2025186214A1 (en) | 2024-03-05 | 2025-09-12 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020017295A1 (en) | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
| US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| WO2004028480A2 (en) | 2002-09-30 | 2004-04-08 | The Regents Of The University Of California | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof |
| EP1601657A1 (en) | 2003-03-12 | 2005-12-07 | Vertex Pharmaceuticals Incorporated | Pyrazole modulators of atp-binding cassette transporters |
| JP4851933B2 (ja) | 2003-04-11 | 2012-01-11 | ピーティーシー セラピューティクス，インコーポレーテッド | １，２，４−オキサジアゾール安息香酸化合物ならびにナンセンス抑制及び疾患の治療のためのその使用 |
| US7696244B2 (en) | 2003-05-16 | 2010-04-13 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
| DE602004022819D1 (de) | 2003-06-06 | 2009-10-08 | Vertex Pharma | Von atp-bindende kassette transportern |
| CA2465565A1 (en) * | 2003-06-12 | 2004-12-12 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| KR20060121909A (ko) | 2003-10-08 | 2006-11-29 | 버텍스 파마슈티칼스 인코포레이티드 | 사이클로알킬 또는 피라닐 그룹을 포함하는 ａｔｐ-결합카세트 수송자의 조절자 |
| RU2006120549A (ru) | 2003-11-14 | 2007-12-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Тиазолы и оксазолы, применяемые в качестве модуляторов транспортеров арт-связывающей кассеты |
| BRPI0509282A (pt) | 2004-03-30 | 2007-09-18 | Univ California | compostos contendo hidrazida inibidores de cftr e seus usos |
| AU2005251745A1 (en) | 2004-06-04 | 2005-12-22 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
| BR122018075478B8 (pt) | 2004-06-24 | 2023-10-31 | Vertex Pharma | moduladores de transportadores de cassete de ligação de atp |
| WO2006044503A2 (en) | 2004-10-13 | 2006-04-27 | Ptc Therapeutics, Inc. | Compounds for nonsense suppression, use of these compounds for the manufacture of a medicament for treating somatic mutation-related diseases |
| JP5385605B2 (ja) | 2005-03-11 | 2014-01-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｐ結合カセットトランスポーターのモジュレーター |
| CA2600869A1 (en) | 2005-03-18 | 2006-09-28 | The Regents Of The University Of California | Compounds having activity in correcting mutant-cftr processing and uses thereof |
| WO2006110483A1 (en) | 2005-04-08 | 2006-10-19 | Ptc Therapeutics, Inc. | Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
| ATE533749T1 (de) | 2005-05-24 | 2011-12-15 | Vertex Pharma | Modulatoren von atp-bindenden kassettentransportern |
| JP2009511494A (ja) | 2005-10-06 | 2009-03-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｐ結合カセットトランスポーターのモジュレーター |
| ES2778846T3 (es) | 2005-11-08 | 2020-08-12 | Vertex Pharma | Moduladores heterocíclicos de transportadores de casete de unión a ATP |
| ATE499363T1 (de) | 2007-05-07 | 2011-03-15 | Novartis Ag | Organische verbindungen |
| MX2010002974A (es) * | 2007-09-14 | 2010-07-29 | Vertex Pharma | Formas solidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4- dihidro-4-oxoquinolin-3-carboxamida. |
| CN101910156B (zh) * | 2007-12-07 | 2013-12-04 | 沃泰克斯药物股份有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的固体形式 |
| NZ585789A (en) | 2007-12-10 | 2012-03-30 | Novartis Ag | Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel |
| MX2010013675A (es) | 2008-06-10 | 2011-02-15 | Novartis Ag | Derivados de pirazina como bloqueadores del canal de sodio epitelial. |
| CA2733908C (en) * | 2008-08-13 | 2017-05-30 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| EP2349223A2 (en) | 2008-09-29 | 2011-08-03 | Vertex Pharmaceuticals Incorporated | Dosage units of 3-(6-(1-(2,2-difluorobenzo [d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| CN102803234A (zh) * | 2009-06-02 | 2012-11-28 | 霓坎制药有限责任公司 | 用于治疗疾病的人甲酰基肽受体的拮抗作用 |
| JP2011034380A (ja) * | 2009-08-03 | 2011-02-17 | Nitto Denko Corp | タッチパネルおよびタッチパネル付表示装置 |
| WO2011028740A1 (en) | 2009-09-03 | 2011-03-10 | Glaxo Group Limited | ENaC BLOCKERS |
| WO2011079087A1 (en) | 2009-12-23 | 2011-06-30 | Glaxo Group Limited | Enac blockers |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| AR081760A1 (es) * | 2010-04-07 | 2012-10-17 | Vertex Pharma | Una composicion farmaceutica para administracion oral que comprende acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico, un metodo para producir la misma, una tableta y una forma unitaria de dosificacion oral que la comprende y el uso de la misma para la fabricacion de un medicamento |
| EP3138563A1 (en) * | 2010-04-22 | 2017-03-08 | Vertex Pharmaceuticals Inc. | Pharmaceutical compositions and administrations thereof |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| US10105356B2 (en) * | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| US9968607B2 (en) | 2011-04-25 | 2018-05-15 | Hetero Research Foundation | Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof |
| WO2013112804A1 (en) * | 2012-01-25 | 2013-08-01 | Vertex Pharmaceuticals Incorporated | Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| DK2914248T4 (da) * | 2012-11-02 | 2024-01-02 | Vertex Pharma | Farmaceutiske sammensætninger til behandlingen af cftr medierede sygdomme |
| RU2016122882A (ru) * | 2013-11-12 | 2017-12-19 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний |
-
2013
- 2013-11-01 DK DK13792149.0T patent/DK2914248T4/da active
- 2013-11-01 HR HRP20181740TT patent/HRP20181740T4/hr unknown
- 2013-11-01 IL IL283276A patent/IL283276B2/en unknown
- 2013-11-01 PL PL13792149.0T patent/PL2914248T5/pl unknown
- 2013-11-01 PT PT13792149T patent/PT2914248T/pt unknown
- 2013-11-01 LT LTEP18192504.1T patent/LT3470063T/lt unknown
- 2013-11-01 EP EP24223819.4A patent/EP4556008A3/en active Pending
- 2013-11-01 DK DK18192504.1T patent/DK3470063T3/da active
- 2013-11-01 SG SG10201913581UA patent/SG10201913581UA/en unknown
- 2013-11-01 PT PT181925041T patent/PT3470063T/pt unknown
- 2013-11-01 TW TW102139864A patent/TW201422253A/zh unknown
- 2013-11-01 TW TW107117580A patent/TWI736768B/zh active
- 2013-11-01 ES ES13792149T patent/ES2694290T5/es active Active
- 2013-11-01 US US14/069,571 patent/US20140163068A1/en not_active Abandoned
- 2013-11-01 SI SI201331163T patent/SI2914248T2/sl unknown
- 2013-11-01 PL PL18192504.1T patent/PL3470063T3/pl unknown
- 2013-11-01 HU HUE18192504A patent/HUE070382T2/hu unknown
- 2013-11-01 FI FIEP18192504.1T patent/FI3470063T3/fi active
- 2013-11-01 WO PCT/US2013/067952 patent/WO2014071122A1/en not_active Ceased
- 2013-11-01 MX MX2015005559A patent/MX368353B/es active IP Right Grant
- 2013-11-01 HU HUE13792149A patent/HUE039864T2/hu unknown
- 2013-11-01 SI SI201332096T patent/SI3470063T1/sl unknown
- 2013-11-01 SM SM20250078T patent/SMT202500078T1/it unknown
- 2013-11-01 RS RS20181318A patent/RS57831B2/sr unknown
- 2013-11-01 KR KR1020157014464A patent/KR102396897B1/ko active Active
- 2013-11-01 NZ NZ708474A patent/NZ708474A/en unknown
- 2013-11-01 CA CA2890106A patent/CA2890106C/en active Active
- 2013-11-01 CN CN202010527346.2A patent/CN111671751A/zh active Pending
- 2013-11-01 LT LTEP13792149.0T patent/LT2914248T/lt unknown
- 2013-11-01 JP JP2015540796A patent/JP6302923B2/ja active Active
- 2013-11-01 RS RS20250226A patent/RS66596B1/sr unknown
- 2013-11-01 FI FIEP13792149.0T patent/FI2914248T4/fi active
- 2013-11-01 ES ES18192504T patent/ES3009747T3/es active Active
- 2013-11-01 CN CN201380066317.9A patent/CN104869982A/zh active Pending
- 2013-11-01 BR BR112015009913-0A patent/BR112015009913B1/pt active IP Right Grant
- 2013-11-01 SG SG11201503365YA patent/SG11201503365YA/en unknown
- 2013-11-01 EP EP18192504.1A patent/EP3470063B1/en active Active
- 2013-11-01 TR TR2018/15218T patent/TR201815218T4/tr unknown
- 2013-11-01 UA UAA201505319A patent/UA117464C2/uk unknown
- 2013-11-01 AU AU2013337730A patent/AU2013337730B2/en active Active
- 2013-11-01 SM SM20180590T patent/SMT201800590T1/it unknown
- 2013-11-01 EP EP13792149.0A patent/EP2914248B2/en active Active
- 2013-11-01 HR HRP20250100TT patent/HRP20250100T1/hr unknown
- 2013-11-01 NZ NZ745659A patent/NZ745659A/en unknown
- 2013-11-01 UA UAA201803746A patent/UA123631C2/uk unknown
- 2013-11-01 SG SG10201703452PA patent/SG10201703452PA/en unknown
- 2013-11-04 AR ARP130104018A patent/AR093340A1/es not_active Application Discontinuation
-
2015
- 2015-04-30 IL IL238551A patent/IL238551B/en active IP Right Grant
- 2015-04-30 CL CL2015001148A patent/CL2015001148A1/es unknown
- 2015-04-30 MX MX2019011662A patent/MX2019011662A/es unknown
-
2016
- 2016-05-11 US US15/152,092 patent/US20160324846A1/en not_active Abandoned
-
2018
- 2018-03-05 JP JP2018038741A patent/JP2018090626A/ja not_active Withdrawn
- 2018-09-14 AU AU2018229528A patent/AU2018229528A1/en not_active Abandoned
- 2018-11-30 CY CY20181101277T patent/CY1121070T1/el unknown
-
2019
- 2019-05-07 JP JP2019087813A patent/JP7003085B2/ja active Active
- 2019-12-20 US US16/722,290 patent/US20200338063A1/en not_active Abandoned
-
2020
- 2020-06-17 AU AU2020204037A patent/AU2020204037B2/en active Active
-
2021
- 2021-12-28 JP JP2021214209A patent/JP2022034069A/ja active Pending
-
2022
- 2022-12-30 US US18/091,472 patent/US20230364073A1/en active Pending
-
2024
- 2024-01-16 AU AU2024200273A patent/AU2024200273A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3470063T3 (fi) | Lääkekoostumuksia cftr-välitteisten sairauksien hoitoon | |
| NZ603043A (en) | Pharmaceutical compositions comprising cftr modulators and administrations thereof | |
| HRP20200664T1 (hr) | Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il) benzojeve kiseline | |
| HRP20190660T1 (hr) | FORMULACIJA N-[2,4-bis(1,1-DIMETILETIL)-5-HIDROKSIFENIL]-1,4-DIHIDRO-4-OKSOHINOLIN-3-KARBOKSAMIDA U OBLIKU TABLETE ZA UPOTREBU U TRETMANU CISTIČNE FIBROZE | |
| EA029081B9 (ru) | Комбинированный состав двух противовирусных соединений | |
| IL274488B2 (en) | Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | |
| SG190448A1 (en) | Rapidly dispersing granules, orally disintegrating tablets and methods | |
| NZ607118A (en) | C-met modulator pharmaceutical compositions | |
| CA2757418C (en) | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same | |
| NZ600231A (en) | Pharmaceutical compositions comprising sigma receptor ligands | |
| JP2015145426A5 (cg-RX-API-DMAC7.html) | ||
| IL214086A (en) | Malt salt of n- {4 - {[7,6- bis (methyllaxy) quinoline-4-yl] oxy} phenyl) - n- (4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms for cancer treatment | |
| NZ603042A (en) | Pharmaceutical compositions comprising cftr modulators and administrations thereof | |
| IN2014CN04127A (cg-RX-API-DMAC7.html) | ||
| SG178975A1 (en) | Indenone derivative and pharmaceutical composition comprising same | |
| SI3029039T1 (en) | Pharmaceutical formulations containing crystalline forms of (R) -7-chloro-N- (quinuclidin-3-yl) benzo (b) thiophene-2-carboxamide hydrochloride monohydrate | |
| NZ628993A (en) | Pharmaceutical formulations comprising ccr3 antagonists | |
| WO2009156837A3 (en) | Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt | |
| HRP20150356T1 (hr) | Kristalni oblici soli prasugrela | |
| IL266097B (en) | " a mono-orotate acid addition salt of (r)-5-((e)-2-pyrrolidin-3-ylvinyl)pyrimidine” | |
| WO2014014794A3 (en) | Mineralocorticoid receptor antagonists | |
| WO2014006636A3 (en) | Stable compositions of fesoterodine | |
| TN2010000120A1 (en) | Galenical formulations of organic compounds | |
| IN2014CN02022A (cg-RX-API-DMAC7.html) | ||
| WO2012060594A3 (ko) | 티오우레아계 화합물 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 항염증 조성물 |